Atea Pharmaceuticals, Inc.
AVIR Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.04
KIRA · Stoqly’s AI analyst, in plain words
- Atea Pharmaceuticals, Inc. lost $158M in fiscal 2025.
- Atea Pharmaceuticals, Inc. returned $25.5M to shareholders in fiscal 2025. The diluted share count fell 3.3%.
Market cap
$323M
P/E
—
Revenue
—
Net income
−$158M
Free cash flow
—
Operating margin
—
Atea Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$158M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Atea Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Atea Pharmaceuticals, Inc.
- CIK
- 0001593899
Atea Pharmaceuticals, Inc. · AVIR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $351M | — | — | — | — |
| Revenue growth | 622.5% | — | — | — | — |
| Operating margin | 39.4% | — | — | — | — |
| Net income | $121M | −$116M | −$136M | −$168M | −$158M |
| Net margin | 34.5% | — | — | — | — |
| Diluted EPS | $1.37 | −$1.39 | −$1.63 | −$2.00 | −$1.94 |
| Cash | |||||
| Cash from operations | −$87.0M | −$121M | −$85.4M | −$135M | −$132M |
| Capital expenditure | $0.0M | $1.9M | — | — | — |
| Free cash flow | −$87.0M | −$123M | — | — | — |
| FCF margin | −24.8% | — | — | — | — |
| Share buybacks | — | — | — | $0.0M | $25.5M |
| Share count change | 308.7% | −5.7% | 0.2% | 1.0% | −3.3% |
| Debt and strength | |||||
| Cash and short-term investments | $764M | $647M | $578M | $455M | $302M |
| Shareholders' equity | $710M | $641M | $555M | $439M | $275M |
| Current ratio | 13.6x | 35.8x | 18.2x | 24.9x | 7.8x |
| Returns and quality | |||||
| Return on equity | 19.3% | −17.2% | −22.7% | −33.9% | −44.3% |
| Return on tangible equity | 17.1% | −18.1% | −24.5% | −38.4% | −57.5% |
| Piotroski F-score | 4 | — | — | — | — |
| Altman Z'' | 19.4 | 30.4 | 17.9 | 18.8 | 3.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Atea Pharmaceuticals, Inc. · AVIR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.04 a share, the company is worth $323M.
Source: SEC EDGAR XBRL filings (CIK 0001593899). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.